Magaly Villafradez-Diaz, MD
Rheumatology · Sanford, FLNPI 1053575050
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 728 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,655 and has fallen 53.1% since, to $1,713 in 2025.
Across 728 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$2K
- Pfizer$1K
- Mallinckrodt Hospital Products Inc.$1K
- GSK$866
- UCB, Inc.$796
- plus $5K from 25 others
Across 1 payment — averaging $15,900 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$16K
What the payments were for
- Food & beverage$13,33098%
- Education$2402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 145 | $2,397 |
| AbbVie | 109 | $2,305 |
| Pfizer | 90 | $1,409 |
| Mallinckrodt Hospital Products Inc. | 54 | $1,244 |
| GSK | 49 | $866 |
| UCB, Inc. | 48 | $796 |
| Mallinckrodt Enterprises LLC | 37 | $694 |
| Johnson & Johnson(3 entities) | 29 | $569 |
| Lilly USA, LLC | 25 | $491 |
| Novartis | 24 | $463 |
| Boehringer Ingelheim | 11 | $372 |
| Sanofi | 13 | $314 |
| Janssen Scientific Affairs, LLC | 2 | $235 |
| Genentech USA, Inc. | 25 | $219 |
| AstraZeneca(2 entities) | 11 | $216 |
| Radius Health, Inc. | 8 | $172 |
| E.r. Squibb & Sons, L.L.C. | 9 | $144 |
| Sobi, Inc | 8 | $133 |
| Aurinia Pharma U.S., Inc. | 6 | $99 |
| Antares Pharma, Inc. | 5 | $85 |
| ANI Pharmaceuticals, Inc. | 5 | $81 |
| Medexus Pharma, Inc. | 3 | $53 |
| Bristol Myers Squibb | 3 | $44 |
| Bioventus LLC | 1 | $42 |
| Actelion Pharmaceuticals US, Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Pacira Therapeutics, Inc. | 1 | $18 |
| Sandoz | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,569 in reported general payments places this provider in the 65th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 18 | $146,115 |
| Enbrel SureclickEtanercept | 13 | $96,065 |
| Hydroxychloroquine Sulfate | 341 | $12,543 |
| Pilocarpine Hcl | 92 | $6,178 |
| Mycophenolate Mofetil | 33 | $4,778 |
| Leflunomide | 97 | $3,981 |
| Duloxetine Hcl | 146 | $3,084 |
| Gabapentin | 179 | $2,993 |
| Lidocaine | 13 | $2,951 |
| MethotrexateMethotrexate Sodium | 84 | $2,291 |
| Colchicine | 21 | $1,863 |
| Methocarbamol | 63 | $1,499 |
| Celecoxib | 29 | $1,184 |
| Baclofen | 58 | $1,107 |
| Nabumetone | 45 | $1,047 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Sanford
- Alvin WellsDestin$2.4M
- Guillermo ValenzuelaPlantation$1.5M
- Julio Gonzalez-PaoliTampa$1.4M
- Ernesto RodriguezZephyrhills$958K
- Vinicius Costa Diniz DominguesDaytona Beach$921K
- Jonathan GreerBoynton Beach$757K
- Jigar ShahMargate$750K
- Rachel TateHollywood$729K
- Howard BuschLoxahatchee$717K
- Michael WeitzMiami$658K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.